Nordea Investment Management AB Purchases 45,507 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Nordea Investment Management AB raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 6.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 770,870 shares of the biopharmaceutical company’s stock after purchasing an additional 45,507 shares during the quarter. Nordea Investment Management AB owned 0.06% of Gilead Sciences worth $71,113,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. First City Capital Management Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $212,000. Central Pacific Bank Trust Division increased its stake in shares of Gilead Sciences by 6.3% during the fourth quarter. Central Pacific Bank Trust Division now owns 15,158 shares of the biopharmaceutical company’s stock valued at $1,400,000 after buying an additional 894 shares during the period. Everence Capital Management Inc. lifted its stake in Gilead Sciences by 1.5% in the fourth quarter. Everence Capital Management Inc. now owns 34,790 shares of the biopharmaceutical company’s stock worth $3,214,000 after acquiring an additional 530 shares during the period. Modus Advisors LLC increased its position in Gilead Sciences by 4.6% during the 4th quarter. Modus Advisors LLC now owns 10,974 shares of the biopharmaceutical company’s stock valued at $1,014,000 after purchasing an additional 487 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of Gilead Sciences by 19.3% during the fourth quarter. GAMMA Investing LLC now owns 18,228 shares of the biopharmaceutical company’s stock valued at $1,684,000 after purchasing an additional 2,955 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 8,500 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the sale, the chief financial officer now directly owns 132,373 shares in the company, valued at approximately $12,173,021.08. The trade was a 6.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 453,734 shares of company stock worth $41,902,086 in the last 90 days. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of analyst reports. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Piper Sandler increased their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Mizuho upped their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Twelve investment analysts have rated the stock with a hold rating, twelve have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Check Out Our Latest Analysis on Gilead Sciences

Gilead Sciences Stock Performance

NASDAQ GILD opened at $90.63 on Wednesday. The stock has a market capitalization of $112.95 billion, a price-to-earnings ratio of 1,007.00, a PEG ratio of 2.24 and a beta of 0.18. The stock has a 50-day moving average of $91.91 and a 200 day moving average of $82.98. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90.

Gilead Sciences (NASDAQ:GILDGet Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the company posted $2.29 EPS. The business’s quarterly revenue was up 7.0% on a year-over-year basis. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.40%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Stories

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.